GLOBAL HEPATOCELLULAR CARCINOMA MARKET (2024 - 2030)
The Hepatocellular Carcinoma Market was valued at USD 1.85 billion in 2023 and is projected to reach a market size of USD 3.21 billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 8.20%.
There is a type of primary cancer that arises from the hepatocytes. The disease is more prevalent in people with diabetes. The majority of the diagnosis of this condition is done by several tests. Targeted drug therapy is included in the treatment. Patients with end-stage of liver function have majority of HCC.
Key Market Insights:
Hepatocellular Carcinoma Market Drivers:
Rising HCC Cases in the U.S. and Breakthroughs in Cyramza Research by Eli Lilly Driving the Market Growth
According to the survey by the Health Science Department, the University of California, Los Angeles, has found that HCC is the most common type of cancer in the U.S. More than 28,000 deaths are reported from the disease, with almost 40,000 Americans diagnosed with it in the last year. Eli Lilly and Company completed Phase 3 research study of Cyramza as a single agent in the second-line treatment of people suffering from hepatocellular carcinoma.
Novel drugs are getting approval driving market growth:
The approval of novel drugs by the regulatory agencies for the treatment of hepatocellular carcinoma is enhancing the growth of the market. In April of last year, the U.S. Regorafenib was expanded by the FDA for the treatment of patients with hepatocellular carcinoma. After the failure of standard treatments, the therapy improved survival for patients. In 2017, the U.S. The FDA granted accelerated approval for the drug nivolumab.
A recent wave of biologic products prescribed for treating HCC is likely to create a lucrative opportunity for market growth. There is still room for improvement in the treatment of HCC, despite the plethora of therapies currently available to patients.
Adoption of biological therapies is increasing driving market growth:
Immune-targeted therapies are used to treat hepatocellular carcinoma. There is a demand for therapies with novel MOAs after Nivolumab was approved for hepatocellular carcinoma.
Over the next few years, many new classes of therapies are looking to enter the global hepatocellular carcinoma treatment market. The market for programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) is growing due to their better clinical profile.
Hepatocellular Carcinoma Market Restraints and Challenges:
The market growth is hampered by the lack of drug approvals. There are no FDA-approved drugs to treat it. The limited availability of treatment processes can limit market growth.
The market growth is hampered by the rising expenditure associated with the various medications. The market's growth is hampered by several diagnostic procedures.
This hepatocellular carcinoma drugs marketplace record gives details of new current trends, trade guidelines, import-export evaluation, manufacturing analysis, cost chain optimization, market percentage, effect of domestic and localized marketplace players, analyses opportunities in terms of rising sales wallet, adjustments in marketplace policies, strategic market increase analysis, market size, class marketplace growths, utility niches and dominance, product approvals, product launches, geographic expansions, technological innovations within the market.
Hepatocellular Carcinoma Market Opportunities:
The manufactures are focused on several strategic collaborations to develop and sell immunotherapies that are indicated to treat wide range of tumors. Bristol-Myers Squibb Company & Ono Pharmaceutical Co. In order to address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan, a strategic collaboration agreement was made with Opdivo. The Phase 2 trials to compare the safety and efficacy of dovitinib and sorafenib in adult patients for treating advanced hepatocellular carcinoma was initiated in 2015.
According to the International Journal of Cancer Research and Treatment, the sixth most common type of cancer worldwide and a third most common cause of death worldwide, is HCC. More than 5% of all cancers are caused by the disease i.e., HCC (Hepatocellular Carcinoma).
GLOBAL HEPATOCELLULAR CARCINOMA MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2022 - 2030 |
|
Base Year |
2023 |
|
Forecast Period |
2024 - 2030 |
|
CAGR |
8.20 % |
|
Segments Covered |
By Treatment Type, End User, route Of Administration and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
Bayer AG, Amgen Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc. |
Hepatocellular Carcinoma Market Segmentation:
Market Segmentation: By Treatment Type:
Based on the treatment type, the radiology treatment segment accounted for the largest revenue share and has led the market. Several other factors such as rising patient awareness, growing demand for various anti-aging treatments, and the surging cost of cosmetic treatments in developed nations are propelling the market growth for radiation therapy. While the demand for immunotherapy is increasing across the globe because of the checkpoint inhibitors has shown strong anti-tumour activity in HCC patients and the result it brings on table is quite acknowledgeable. the combination of the anti-PDL1 antibody atezolizumab and the VEGF-neutralizing antibody bevacizumab will soon become the standard of care as a first-line therapy for HCC. Immunotherapy is the fastest growing segment by treatment type.
Chemotherapy is used to treat advanced hepatocellular carcinoma. The results of two pivotal Phase III placebo-controlled studies show that sorafenib is the standard therapeutic agent for advanced HCC. After the introduction of sorafenib for the treatment of HCC, Phase III trials of other agents as first-line or second-line chemotherapy have been conducted to determine if any of them offer superior survival benefit to sorafenib.
Market Segmentation: By End-User
Hospitals are the largest segment. The fastest-growing segment may be ambulatory surgery centres, which provide specialized treatments like TACE and RFA with convenience and cost-effectiveness. Clinics are the fastest growing segment.
Hospitals are the leading segment due to their comprehensive facilities, advanced diagnostic capabilities, diverse treatment options, and supportive care infrastructure. They offer a centralized setting for diagnosis, staging, treatment, and follow-up, with access to a multidisciplinary team of specialists and advanced diagnostic tools. Hospitals offer a wide range of treatment options and supportive care services to help patients manage their symptoms and improve their quality of life.
Clinics are emerging as the fastest-growing segment for HCC treatment due to several factors that enhance patient convenience, accessibility, and cost-effectiveness. Clinics offer an outpatient setting that gives flexibility and reduces the need for lengthy hospital stays for patients with early-stage HCC. Individualized care tailored to the specific needs of patients is provided by specialized HCC clinics, while technological advancement such as Fibro Scan and Ultrasonic elastography allow non-invasive assessment and diagnosis of HCC. Effective management in clinics has been made possible by the availability of targeted therapies. Continuation of care and improved patient outcomes are provided by clinics.
Market Segmentation: Route of Administration:
Injectables are the leading segment and fastest growing segment is Oral. As injectables are faster to show effects on patients as compared to oral methodology. The leading route of administration for the market is IVs, accounting for 45% of the market share. This is followed by oral administration with a third of the market share. The preferred route of administration for systemic therapies is intravenous administration. Systemic therapies can reach cancer cells throughout the body to prevent them from growing. Targeted therapies are drugs that are designed to target specific cancer cells to prevent them from growing. Regional therapies are treatments that are delivered directly to the liver.
Market Segmentation: Regional Analysis:
North America has a well-developed healthcare infrastructure, advanced diagnostic capabilities, and robust research and development initiatives. The region accounts for over 40% of the total market revenue and is expected to continue growing at a steady pace due to the introduction of new and more effective treatment options. Hospitals and research institutions are leading the development and adoption of innovative therapies, including targeted therapies, immunotherapy, and combination therapies. Patient outcomes and survival rates have improved. Leading researchers and pharmaceutical companies from around the world come to NA for clinical research and trials.
The Asia-Pacific region is rapidly emerging as a major player in the global HCC market, spurred by its burgeoning population, escalating prevalence of HCC risk factors, and expanding healthcare infrastructure. The region is poised to surpass North America in terms of revenue share. The growth trajectory is fuelled by factors such as the widespread prevalence of hepatitis B and C infections, the rapidly aging population, and the active pursuit of innovative therapeutic approaches. Increased market share, enhanced research and development efforts, and expanded opportunities for pharmaceutical companies will result from the Asia-Pacific region's growing prominence. As the region continues to innovate and lead in HCC management, it will undoubtedly remain a driving force in the global market.
COVID-19 Impact Analysis on the Global Hepatocellular Carcinoma Market:
The COVID-19 pandemic has considerably impacted the hepatocellular carcinoma marketplace. As in keeping with studies look at titled "Impacts of COVID-19 on Liver Cancers: During and after the Pandemic", published within the National Library of Medicine in May 2020, hepatocellular carcinoma (HCC) patients are extra susceptible to the outcomes of COVID-19 than other most cancers patients as the hepatic damage caused by SARS-CoV-2 may want to complicate the prevailing hepatitis virus infection and cirrhosis. Further, boundaries to having access to cancer tablets at some stage in the COVID-19 pandemic endangered the steadiness and integrity of pharmaceutical deliver chains, thus limiting the supply of medicine throughout healthcare centers. Thus, the COVID-19 pandemic has altered healthcare priorities, which may additionally adversely impact HCC control.
People with comorbidities were more likely to develop the virus if the diagnostic and treatment processes were delayed. The number of people visiting hospitals for treatment is reduced by these factors. With fewer COVID-19 instances and large-scale vaccination campaigns, the liver cancer treatments market will likely reach its full potential throughout the forecast period.
Latest Trends/ Developments:
The global Hepatocellular Carcinoma Market is reasonably split and fragmented with the existence of several global companies. These players are motivated to achieve higher market share by implementing different strategies, such as acquisitions, partnerships, and investments. Companies are also spending heftily on the development of improved products and infrastructure facilities alongside maintaining competitive pricing. This has further resulted in increased government engagement and the advancement of medical infrastructure.
There is a therapy called Immunotherapy. A type of cancer treatment that harnesses the body's immune system is called immunotherapy. Several clinical trials are currently underway evaluating the efficacy of immunotherapy for the treatment of HCC, and it is showing promise in the treatment of the disease.
Precision medicine. The approach to cancer treatment that tailor’s treatment to the individual patient's genetics is called precision medicine. It is hoped that precision medicine will lead to more effective and personalized treatment options in the future.
Early detection of HCC is crucial for improving the survival chances of the patient. With the help of advancement in technologies and medicine there have been few treatments or techniques to detect HCC are contrast-enhanced ultrasound (CEUS) and Gadoxetate (Gd-EOB-DTPA), Magnetic Resonance Imaging (MRI) is the most common technique for early detection of HCC in the patient.
The research and development of novel treatment alternatives and studying the combination treatment effects of drugs is being done by pharmaceutical companies. AVEO Pharmaceuticals, Inc. The trials of tivozanib plus durvalumab are being conducted in patients with advanced hepatocellular carcinoma.
Key Players:
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
The Global Hepatocellular Carcinoma Market was valued at USD 1.85 billion and is projected to reach a market size of USD 3.21 billion by the end of 2030. Over the forecast period of 2023-2030, the market is projected to grow at a CAGR of 8.20%.
There has been an increase in the Prevalence of Liver Cancer, Noval Drugs are getting approval.
Based on Treatment type, the Hepatocellular Carcinoma Market is segmented into Surgery, Radiation therapy, Chemotherapy, Immunotherapy and Targeted therapy.
North America is the most dominant region for the Global Hepatocellular Carcinoma Market.
Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Onyx Pharmaceuticals, Inc., Pfizer Inc., Taiho Pharmaceutical Co., Ltd.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
